4D Molecular Therapeutics, Inc. FDMT
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is an ophthalmology drug developer. Its lead program, 4D-150, is in Phase 3 for Wet age-related macular degeneration (wet AMD); DME in preparation. Its next catalyst on record is 4D-150: 4FRONT-1 Phase 3 topline data (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: 4D-150 — 4FRONT-1 Phase 3 topline data (Q2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| 4D-150 | Wet AMD (4FRONT-1, 4FRONT-2 Phase 3) | gene therapy | Phase 3 |
| 4D-150 | Diabetic macular edema (single Phase 3 planned) | gene therapy | Phase 2 |
| 4D-710 | Cystic fibrosis lung disease | gene therapy | Phase 2 |
| 4D-175 | Geographic atrophy | gene therapy | Pre-clinical |
| 4D-725 | Alpha-1-antitrypsin deficiency lung disease | gene therapy | Pre-clinical |
Recent results and decisions
- Aug 13, 2026positive PRISM Phase 2b 2-year data (presented at ASRS) showed 78% overall treatment burden reduction (2.7 vs 12.0 injections projected with aflibercept), 87% in recently diagnosed subgroup, no new inflammation cases.
78% overall treatment burden reduction (2.7 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)
Filing - Aug 13, 2026completed enrollment Enrollment completed in June 2026 in the 4FRONT-2 global Phase 3 (N>500 expected randomized).
Enrollment completed in June 2026 with N>500 expected to be randomized; topline data expected in H2 2027
Filing - Mar 18, 2026positive Positive long-term interim AEROW Phase 1/2 data (cutoff Dec 1, 2025): clinically meaningful ppFEV1/LCI2.5 activity and durable CFTR expression at 1 year; no numbers given.
Announced positive long-term interim results from the AEROW Phase 1/2 clinical trial (data cut-off: December 1, 2025)
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.